

**Listing of Claims:**

1. (Currently Amended) A pharmaceutical composition, comprising an agent amyloidogenic protein or fragment thereof effective to induce an immune response against an amyloid component in a patient, and a pharmaceutical excipient an adjuvant that is pharmaceutically acceptable for human administration.
2. (Original) The pharmaceutical composition of claim 1, wherein the amyloid component is a fibril peptide or protein.
3. (Currently Amended) The pharmaceutical composition of claim 2, wherein the amyloid component is derived from a fibril precursor protein selected from the group consisting of proteins or peptides consisting of Serum Amyloid A protein (ApoSSA), immunoglobulin light chain, immunoglobulin heavy chain, ApoAI, transthyretin, lysozyme, fibrogen  $\alpha$  chain, gelsolin, cystatin C, Amyloid  $\beta$  protein precursor ( $\beta$ -APP), Beta<sub>2</sub> microglobulin, prion precursor protein (PrP), atrial natriuretic factor, keratin, islet amyloid polypeptide, a peptide hormone, and synuclein; including mutant proteins, protein fragments and proteolytic peptides thereof variant proteins associated with hereditary amyloidosis.
4. (Original) The pharmaceutical composition of claim 3, wherein said agent induces an immune response directed against a neoepitope formed by said fibril protein or peptide, with respect to a fibril precursor protein.
5. (Original) The pharmaceutical composition of claim 3, wherein said amyloid component is selected from the group consisting of AA, AL, ATTR, AApoA1, Alys, Agel, Acys, A $\beta$ , AB<sub>2</sub>M, AScr, Acal, AIAPP and synuclein-NAC fragment.
6. (Currently Amended) The pharmaceutical composition of claim 5, wherein said agent is selected from the group consisting of AA, AL, ATTR, AApoA1, Agel, Acys, A $\beta$ , AB<sub>2</sub>M, AScr, PrP, Acal, AIAPP and synuclein-NAC fragment.
7. (Original) The pharmaceutical composition of claim 1, wherein said composition comprises an agent effective to induce an immunogenic response against at least two different amyloid components.

8. (Original) The pharmaceutical composition of claim 1, wherein said agent is a peptide linked to a carrier protein.

9. Cancel.

10. (Previously Presented) The pharmaceutical composition of claim 9, wherein said adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, and alum.

11-57. Cancel.